title: Determinants of achieving early blood pressure control with monotherapy in a primary care setting.
abstract: This study sought to identify the determinants of early blood pressure (BP) control associated with monotherapy in hypertensive individuals being managed in the primary care setting. The Valsartan Intensified Primary Care Reduction of Blood Pressure (VIPER-BP) study, was a multicenter, randomized controlled trial of an intensive approach to BP management. During a standardized run-in, 2185 participants commenced monotherapy (valsartan 80 mg/d) for 14 to 28 days. A total of 1978 participants aged 59±12 years (60% men) completed the run-in phase. Of these, 15.1%, 43.5%, and 41.4% participants had an initial BP target of ≤125/75, 130/80, and 140/90 mm Hg, respectively. A total of 416 of 2185 participants (19.0%) subsequently achieved their individual BP target during run-in with a mean BP change of -22.6±12.1/-12.9±8.2 mm Hg vs -4.2±16.2/-3.0±9.6 mm Hg for the rest (P<.001). These early responders were more likely to be women (adjusted odds ratio, 1.41; 95% confidence interval, 1.10-1.80), had lower BP at baseline, were less likely to have been treated previously (or for less time), and had a less stringent BP target. An initial period of monotherapy achieved BP control in a high proportion of hypertensive individuals with key groups (including women and de novo cases) more likely to show an early BP response.
authors.affiliation: Department of Preventative Health and NHMRC Centre of Research Excellence to Reduce Inequality in Heart Disease, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia.
authors.forename: Simon
authors.initials: S
authors.lastname: Stewart
authors.forename: Melinda J
authors.initials: MJ
authors.lastname: Carrington
authors.forename: Carla H
authors.initials: CH
authors.lastname: Swemmer
authors.forename: Nicol P
authors.initials: NP
authors.lastname: Kurstjens
authors.forename: Alex
authors.initials: A
authors.lastname: Brown
authors.forename: Louise M
authors.initials: LM
authors.lastname: Burrell
authors.forename: Mark
authors.initials: M
authors.lastname: Nelson
authors.forename: Nigel P
authors.initials: NP
authors.lastname: Stocks
authors.forename: Garry L
authors.initials: GL
authors.lastname: Jennings
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D019468:Disease Management; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D012737:Sex Factors; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000959:Antihypertensive Agents; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine
references.citation: Lancet. 2005 Jan 15-21;365(9455):217-23
references.pmid: 15652604
references.citation: Int J Cardiol. 2011 Dec 15;153(3):317-22
references.pmid: 21215482
references.citation: Am J Hypertens. 2003 Jan;16(1):39-45
references.pmid: 12517681
references.citation: JAMA. 2012 Mar 28;307(12):1273-83
references.pmid: 22427615
references.citation: JAMA. 2004 Feb 25;291(8):955-64
references.pmid: 14982911
references.citation: Hypertension. 2009 Apr;53(4):646-53
references.pmid: 19237683
references.citation: Hypertension. 2012 Mar;59(3):564-71
references.pmid: 22252396
references.citation: BMJ. 2012 Nov 20;345:e7156
references.pmid: 23169801
references.citation: Ann Emerg Med. 1998 Feb;31(2):214-8
references.pmid: 9472183
references.citation: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005182
references.pmid: 20238338
references.citation: Int J Cardiol. 2010 Dec 3;145(3):461-7
references.pmid: 19573941